Pfizer and Zenith Epigenetics Collaborates to Evaluate ZEN-3694 & Talazoparib for TNBC

 Pfizer and Zenith Epigenetics Collaborates to Evaluate ZEN-3694 & Talazoparib for TNBC

Pfizer and Zenith Epigenetics Collaborates to Evaluate ZEN-3694 & Talazoparib for TNBC

Shots:

  • The collaboration is for the onset of P-Ib/II trial for assessing Zenith’s ZEN-3694 and Pfizer’s talazoparib in patients with LA or MTNBC
  • Pfizer & Zenith to fund the trial with supply of their respective products and will retain rights for their own products
  • ZEN-3694 is an inhibitor of BETi (bromodomain and extra-terminal domain inhibitor) currently evaluated in P-II in combination with enzalutamide for metastatic castration resistant prostate cancer

Click here to read full press release/ article | Ref: Zenith Epigenetics | Image: Omniriga

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post